Photo of Aria F. Olumi, MD

Aria F. Olumi, MD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-4705


aolumi@bidmc.harvard.edu

Photo of Aria F. Olumi, MD

Beth Israel Deaconess Medical Center
Phone: (617) 667-4705


aolumi@bidmc.harvard.edu

Visualize Collaborations
Learn how these members are similar
Similar Members

HCC members that share similar concepts* with Aria F. Olumi, MD but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members

Aria F. Olumi, MD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Janet & William DeWolf endowed Professor, Surgery, Harvard Medical School
  • Chief, Urologic Surgery, Beth Israel Deaconess Medical Center

HCC PROGRAM AFFILIATION

Research Abstract

TRAIL, a recently discovered member of the TNF superfamily of cytokines, may be a useful apoptotic-inducing treatment for prostate cancer. However, better understanding the molecular pathways that render a cell TRAIL-sensitive (PC3 and DU145 cells) vs. TRAIL-resistant (LNCaP cells) is crucial in order to selectively offer TRAIL to patients who would maximally benefit from the drug. The focus of my lab is to delineate the molecular mechanisms between TRAIL-resistant and TRAIL-sensitive prostate cancer cells.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Almohtasib J, Scire E, Kaul S, Fleishman A, Chang P, Wagner A, Bellmunt J, Korets R, Olumi AF, Gershman B. Extended versus Standard Lymph Node Dissection at the Time of Radical Cystectomy for Bladder Cancer. Urology 2026. PubMed
  • Perez-Londono A, Almohtasib J, Kaul S, Fleishman A, Korets R, Chang P, Wagner A, Olumi AF, Garnick M, Gershman B. Baseline Frailty, Treatment Intensity, and Clinical Outcomes Among Older Adults with Locally-advanced Prostate Cancer. Eur Urol Oncol 2026. PubMed
  • Kennedy-Yoon D, Almohtasib J, Kaul S, Fleishman A, Chang P, Wagner A, Bellmunt J, Korets R, Olumi AF, Gershman B. Association of patient, disease, and structural characteristics with receipt of intravesical BCG therapy from 2002-2017 and the impact of BCG supply shortages. Urology 2026. PubMed
  • Gershman B, Perez-Londono A, Almohtasib J, Kaul S, Fleishman A, Boorjian SA, Olumi AF, Linder BJ. Voiding Dysfunction Among Older Adults With Non-Muscle Invasive Bladder Cancer: Incidence and Predictors of Treatment for Overactive Bladder. Neurourol. Urodyn. 2026. PubMed
  • Perez-Londoño A, Kaul S, Fleishman A, Korets R, Rayala H, Chang P, Wagner AA, Bellmunt J, Olumi AF, Gershman B. Repeat transurethral resection and contemporary oncologic outcomes among patients with non-muscle invasive urothelial carcinoma of the bladder. World J Urol 2026; 44:91. PubMed
  • Wang Z, Gu B, Sharkey C, Ge R, Olumi AF. SRD5A2 and emerging therapies in androgen-driven disorders. Nat Rev Urol 2026. PubMed
  • Chang JC, Perez-Londoño A, Kaul S, Almohtasib J, Fleishman A, Korets R, Chang P, Wagner A, Bellmunt J, Olumi AF, Gershman B. Dynamic prognostication of non-muscle invasive bladder cancer using conditional recurrence- and progression-free survival: A SEER-Medicare analysis. Urol Oncol 2025. PubMed
  • Perez-Londoño A, Kaul S, Fleishman A, Korets R, Rayala H, Chang P, Wagner A, Bellmunt J, Olumi AF, Gershman B. Contemporary outcomes and disease burden of high-grade T1 bladder cancer. Can Urol Assoc J 2025. PubMed
  • Yun JH, Mansur A, Abbaspour E, Zakavi SS, Newton CS, Madoff DC, Woodrum D, Georgiades C, Shyn P, Olumi AF, Uppot RN, Kalva S, Kokabi N, Gandhi R, Habibollahi P, Nezami N. The growing armamentarium of image-guided tumor ablation in interventional oncology. 2025; 2:umaf033. PubMed
  • Gershman B, Ernandez J, Kaul S, Perez-Londono A, Fleishman A, Korets R, Chang P, Wagner AA, Kim S, Bellmunt J, Aghdam N, Kim D, McCarthy EP, Olumi AF. Comprehensive characterization of the real-world perioperative morbidity of radical cystectomy in older adults. 2025; 16:102265. PubMed
  • Gershman B, Ernandez J, Kaul S, Perez-Londoño A, Fleishman A, Korets R, Chang P, Wagner AA, Kim S, Bellmunt J, Aghdam N, McCarthy EP, Kim DH, Olumi AF. Associations of a claims-based frailty index with perioperative outcomes and survival among older adults undergoing radical cystectomy for bladder cancer. Urol Oncol 2025. PubMed
  • Yu J, Sharkey C, Olumi AF, Wang Z. Ectonucleotidases and purinergic receptors in mouse prostate gland. Am J Clin Exp Urol 2025; 13:145-155. PubMed
  • Perez-Londono A, Ramos F, Fleishman A, Kaul S, Korets R, Johnson M, Olumi AF, Tsai L, Gershman B. Predicting cancer detection rates from multiparametric prostate MRI: Beyond the PI-RADS classification system. Can Urol Assoc J 2024. PubMed
  • Al-Faouri R, Sharkey C, Gershman B, Tsai LL, Wang Z, Olumi AF. Effect of TNF-α Inhibitor Therapy on Growth of the Prostate Gland. Eur Urol Focus 2024; 10:641-647. PubMed
  • Gulati R, Jiao B, Al-Faouri R, Sharma V, Kaul S, Fleishman A, Wymer K, Boorjian SA, Olumi AF, Etzioni R, Gershman B. Lifetime Health and Economic Outcomes of Biparametric Magnetic Resonance Imaging as First-Line Screening for Prostate Cancer : A Decision Model Analysis. Ann Intern Med 2024. PubMed
  • Sharkey C, Long X, Al-Faouri R, Strand D, Olumi AF, Wang Z. Enhanced prostatic Esr1 luminal epithelial cells in the absence of SRD5A2. J Pathol 2024. PubMed
  • Desmond C, Kaul S, Fleishman A, Korets R, Chang P, Wagner A, Kim SP, Aghdam N, Olumi AF, Gershman B. The association of patient and disease characteristics with the overtreatment of low-risk prostate cancer from 2010 to 2016. Prostate Cancer Prostatic Dis 2024. PubMed
  • Escobar AJ, Krishna S, Flowers KM, Abello A, Gershman B, Wagner AA, Chang P, Korets R, Mistretta CJ, Schreiber KL, Olumi AF, Rayala H. Practical Use of Self-Adjusted Nitrous Oxide (SANO) During Transrectal Prostate Biopsy: A Double-Blind Randomized-Control Trial. J Urol 2023. PubMed
  • Moreno MF, Kaul S, Fleishman A, Korets R, Chang P, Wagner A, Kim S, Bellmunt J, Kaplan I, Olumi AF, Gershman B. Conditional survival following radical cystectomy for urothelial carcinoma of the bladder. Urol Oncol 2023. PubMed
  • Morton E, Kaul S, Fleishman A, Korets R, Chang P, Wagner A, Kim SP, Bellmunt J, Kaplan I, Olumi AF, Gershman B. Urothelial carcinoma of the bladder with isolated lymph node metastasis: Natural history and outcomes following surgical resection. Urol Oncol 2022. PubMed
  • Estevez A, Kaul S, Fleishman A, Korets R, Chang P, Wagner A, Bellmunt J, Olumi AF, Rayala H, Gershman B. Disparities in the prevalence and management of high-risk non-muscle invasive bladder cancer. Urol Oncol 2022. PubMed
  • Schaufler C, Kaul S, Fleishman A, Korets R, Chang P, Wagner A, Kim S, Bellmunt J, Kaplan I, Olumi AF, Gershman B. Immediate radiotherapy versus observation in patients with node-positive prostate cancer after radical prostatectomy. Prostate Cancer Prostatic Dis 2022. PubMed
  • Ramos F, Korets R, Fleishman A, Kaul S, Johnson M, Wei JL, Olumi AF, Tsai LL, Gershman B. Comparative Effectiveness of Magnetic Resonance Imaging-Ultrasound Fusion Versus In-bore Magnetic Resonance Imaging-targeted Prostate Biopsy. Urology 2022. PubMed
  • Bharadwaj M, Kaul S, Fleishman A, Korets R, Chang P, Wagner A, Kim S, Bellmunt J, Kaplan I, Olumi AF, Gershman B. Adjuvant chemotherapy versus observation following radical cystectomy for locally advanced urothelial carcinoma of the bladder. Urol Oncol 2022. PubMed
  • Vaselkiv JB, Ceraolo C, Wilson KM, Pernar CH, Rencsok EM, Stopsack KH, Grob ST, Plym A, Giovannucci EL, Olumi AF, Kibel AS, Preston MA, Mucci LA. 5-alpha reductase inhibitors and prostate cancer mortality among men with regular access to screening and health care. Cancer Epidemiol Biomarkers Prev 2022. PubMed
  • Softness K, Kaul S, Fleishman A, Efstathiou J, Bellmunt J, Kim SP, Korets R, Chang P, Wagner A, Olumi AF, Gershman B. Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder. Urol Oncol 2022. PubMed
  • Sharkey C, Long X, Wang Z, Al-Faouri R, Gershman B, Tsai LL, Olumi AF. Zonal Growth Pattern of the Prostate Is Affected by Age and Body Mass Index. J Urol 2022; 207:876-884. PubMed
  • Liu S, Wang Z, Long X, Fleishman A, Huang X, Wu Q, Gershman B, Olumi AF. Single black men have the worst prognosis with localized prostate cancer. Can J Urol 2022; 29:10992-11002. PubMed
  • Reitblat C, Fleishman A, Kaplan IA, Stensland KD, D'Amico AV, Olumi AF, Wagner AA, Chang PK, Kim SP, Korets R, Gershman B. Radical prostatectomy versus external beam radiation therapy for high-grade, clinically localized prostate cancer: Emulation of a target clinical trial. Urol Oncol 2021. PubMed
  • Tao Z, Shi L, Parke J, Zheng L, Gu W, Dong XC, Liu D, Wang Z, Olumi AF, Cheng Z. Sirt1 coordinates with ERα to regulate autophagy and adiposity. Cell Death Discov 2021; 7:53. PubMed
  • Unadkat P, Fleishman A, Olumi AF, Wagner A, Chang P, Kim SP, Korets R, Gershman B. Contemporary Incidence and Predictors of Occult Inguinal Lymph Node Metastases in Men with Clinically Node-Negative (cN0) Penile Cancer. Urology 2021. PubMed
  • McConkey D, Best CJM, Gumminger JA, Olumi AF. "Advancing bladder preservation: Biomarkers, decision-making, and therapy". Urol Oncol 2021. PubMed
  • Wu S, Lin SX, Wirth GJ, Lu M, Lu J, Subtelny AO, Wang Z, Olumi AF, Dahl DM, Blute ML, Wu CL. Long-term Oncologic Impact of Positive Anterior and Posterior Surgical Margins After Radical Prostatectomy. Am J Clin Oncol 2020. PubMed
  • Unadkat P, Olumi AF, Gershman B. The Role of Lymphadenectomy in Patients with Advanced Renal Cell Carcinoma. Urol Clin North Am 2020; 47:371-377. PubMed
  • Liu D, Shoag JE, Poliak D, Goueli RS, Ravikumar V, Redmond D, Vosoughi A, Fontugne J, Pan H, Lee D, Thomas D, Salari K, Wang Z, Romanel A, Te A, Lee R, Chughtai B, Olumi AF, Mosquera JM, Demichelis F, Elemento O, Rubin MA, Sboner A, Barbieri CE. Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. Nat Commun 2020; 11:1987. PubMed
  • Zhang H, Frendl D, Wang Z, Olumi AF. High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5 Alpha-Reductase Inhibitors for Benign Prostatic Hyperplasia. J Urol 2020. PubMed
  • Xue B, Wu S, Sharkey C, Tabatabaei S, Wu CL, Tao Z, Cheng Z, Strand D, Olumi AF, Wang Z. Obesity-associated inflammation induces androgenic to estrogenic switch in the prostate gland. Prostate Cancer Prostatic Dis 2020. PubMed
  • Wang Z, Deng T, Long X, Lin X, Wu S, Wang H, Ge R, Zhang Z, Wu CL, Taplin ME, Olumi AF. Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy. PLoS ONE 2020; 15:e0229754. PubMed
  • Wu S, Lin X, Lin SX, Lu M, Deng T, Wang Z, Olumi AF, Dahl DM, Wang D, Blute ML, Wu CL. Impact of biopsy perineural invasion on the outcomes of patients who underwent radical prostatectomy: a systematic review and meta-analysis. Scand J Urol 2019. PubMed
  • Wu S, Lin SX, Lu M, Subtelny AO, Wang Z, Dahl DM, Olumi AF, Wu CL. Assessment of 5-year overall survival in bladder cancer patients with incidental prostate cancer identified at radical cystoprostatectomy. Int Urol Nephrol 2019. PubMed
  • Wu S, Lin SX, Wirth GJ, Lu M, Lu J, Subtelny AO, Wang Z, Dahl DM, Olumi AF, Wu CL. Impact of Multifocality and Multilocation of Positive Surgical Margin After Radical Prostatectomy on Predicting Oncological Outcome. Clin Genitourin Cancer 2018. PubMed
  • Yun H, Bedolla R, Horning A, Li R, Chiang HC, Huang TH, Reddick R, Olumi AF, Ghosh R, Kumar AP. BRCA1 Interacting Protein COBRA1 Facilitates Adaptation to Castrate-Resistant Growth Conditions. Int J Mol Sci 2018. PubMed
  • Vandergrift LA, Decelle EA, Kurth J, Wu S, Fuss TL, DeFeo EM, Halpern EF, Taupitz M, McDougal WS, Olumi AF, Wu CL, Cheng LL. Metabolomic Prediction of Human Prostate Cancer Aggressiveness: Magnetic Resonance Spectroscopy of Histologically Benign Tissue. Sci Rep 2018; 8:4997. PubMed
  • Wu S, Ye J, Wang Z, Lin SX, Lu M, Liang Y, Zhu X, Olumi AF, Zhong WD, Wu CL. Expression of aromatase in tumor related stroma is associated with human bladder cancer progression. Cancer Biol Ther 2018. PubMed
  • Ingham MD, Lee RJ, MacDermed D, Olumi AF. Prostate cancer in transgender women. Urol Oncol 2018; 36:518-525. PubMed
  • Wang Z, Olumi AF. Metformin: an anti-proliferative agent and methylation regulator in treating prostatic disease? Am J Physiol Renal Physiol 2017. PubMed
  • Wang Z, Hu L, Salari K, Bechis S, Ge R, Wu S, Rassoulian C, Pham J, Wu CL, Tabatabaei S, Douglas SW, Olumi AF. Androgenic to estrogenic switch in human adult prostate gland is regulated by epigenetic silencing of steroid 5α-reductase 2. J Pathol 2017. PubMed
  • Rodin D, Drumm M, Clayman R, Buscariollo DL, Galland-Girodet S, Eidelman A, Feldman AS, Dahl DM, McGovern FJ, Olumi AF, Niemierko A, Shipley WU, Zietman AL, Efstathiou JA. Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-term Results of a Single-institution Experience. Clin Genitourin Cancer 2017. PubMed
  • Frendl DM, Olumi AF. Understanding temporal trends in medical costs associated with progression to metastatic prostate cancer. Cancer 2017. PubMed
  • Wang Z, Xiao X, Ge R, Li J, Johnson CW, Rassoulian C, Olumi AF. Metformin inhibits the proliferation of benign prostatic epithelial cells. PLoS ONE 2017; 12:e0173335. PubMed
  • Ge R, Wang Z, Wu S, Zhuo Y, Otsetov AG, Cai C, Zhong W, Wu CL, Olumi AF. Metformin represses cancer cells via alternate pathways in N-cadherin expressing vs. N-cadherin deficient cells. 2015. PubMed
  • Bechis SK, Otsetov AG, Ge R, Wang Z, Vangel MG, Wu CL, Tabatabaei S, Olumi AF. Age and Obesity Promote Methylation and Suppression of 5α-Reductase 2: Implications for Personalized Therapy of Benign Prostatic Hyperplasia. J Urol 2015. PubMed
  • Yun H, Xie J, Olumi AF, Ghosh R, Kumar AP. Activation of AKR1C1/ERβ induces apoptosis by downregulation of c-FLIP in prostate cancer cells: A prospective therapeutic opportunity. 2015. PubMed
  • Ge R, Wang Z, Bechis SK, Otsetov AG, Hua S, Wu S, Wu CL, Tabatabaei S, Olumi AF. DNA methyl transferase 1 reduces expression of SRD5A2 in the aging adult prostate. Am J Pathol 2015; 185:870-82. PubMed
  • Preston MA, Riis AH, Ehrenstein V, Breau RH, Batista JL, Olumi AF, Mucci LA, Adami HO, Sørensen HT. Metformin use and prostate cancer risk. Eur Urol 2014. PubMed
  • Rodríguez D, Preston MA, Barrisford GW, Olumi AF, Feldman AS. Clinical features of leiomyosarcoma of the urinary bladder: analysis of 183 cases. Urol Oncol 2014. PubMed
  • Preston MA, Wilson KM, Markt SC, Ge R, Morash C, Stampfer MJ, Loda M, Giovannucci E, Mucci LA, Olumi AF. 5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med 2014. PubMed
  • Bechis SK, Otsetov AG, Ge R, Olumi AF. Personalized medicine for the management of benign prostatic hyperplasia. J Urol 2014. PubMed
  • Xu R, Horick N, McGovern FJ, Dahl DM, Feldman AS, Blute ML, Olumi AF, Michaelson MD. Prognostic significance of indeterminate lung nodules in renal cell carcinoma. Urol Oncol 2014; 32:355-61. PubMed
  • Aizer AA, Paly JJ, Michaelson MD, Rao SK, Nguyen PL, Kaplan ID, Niemierko A, Olumi AF, Efstathiou JA. Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer. J Oncol Pract 2014; 10:107-12. PubMed
  • Yang H, Chen X, Wang X, Li Y, Chen S, Qian X, Wang R, Chen L, Han W, Ruan A, Du Q, Olumi AF, Zhang X. Inhibition of PP2A activity confers a TRAIL-sensitive phenotype during malignant transformation. Mol Cancer Res 2014; 12:217-27. PubMed
  • Rodríguez D, Barrisford GW, Sanchez A, Preston MA, Kreydin EI, Olumi AF. Primary spermatic cord tumors: disease characteristics, prognostic factors, and treatment outcomes. Urol Oncol 2014; 32:52.e19-25. PubMed
  • Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Models of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw 2013; 11:1364-72. PubMed
  • Olumi AF, Kaufman DS, Zietman A, Harisinghani MG, Wu CL. Case records of the Massachusetts General Hospital. Case 25-2013. A 71-year-old man with hematuria and a mass in the bladder. N Engl J Med 2013; 369:660-7. PubMed
  • Fendt SM, Bell EL, Keibler MA, Davidson SM, Wirth GJ, Fiske B, Mayers JR, Schwab M, Bellinger G, Csibi A, Patnaik A, Blouin MJ, Cantley LC, Guarente L, Blenis J, Pollak MN, Olumi AF, Vander Heiden MG, Stephanopoulos G. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res 2013; 73:4429-38. PubMed
  • Gameiro PA, Yang J, Metelo AM, Pérez-Carro R, Baker R, Wang Z, Arreola A, Rathmell WK, Olumi A, López-Larrubia P, Stephanopoulos G, Iliopoulos O. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab 2013; 17:372-85. PubMed
  • Rodríguez D, Olumi AF. Management of spermatic cord tumors: a rare urologic malignancy. Ther Adv Urol 2012; 4:325-34. PubMed
  • Olumi AF. Editorial comment. J Urol 2012; 188:2107. PubMed
  • Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol 2012; 30:3071-6. PubMed
  • Lu J, Wirth GJ, Wu S, Chen J, Dahl DM, Olumi AF, Young RH, McDougal WS, Wu CL. A close surgical margin after radical prostatectomy is an independent predictor of recurrence. J Urol 2012; 188:91-7. PubMed
  • Niu Y, Ge R, Hu L, Diaz C, Wang Z, Wu CL, Olumi AF. Reduced levels of 5-α reductase 2 in adult prostate tissue and implications for BPH therapy. Prostate 2011. PubMed
  • Psutka SP, Feldman AS, Rodin D, Olumi AF, Wu CL, McDougal WS. Men with organ-confined prostate cancer and positive surgical margins develop biochemical failure at a similar rate to men with extracapsular extension. Urology 2011. PubMed
  • Olumi AF. Editorial Comment. J Urol 2009. PubMed
  • Zhang X,Huang X,Olumi AF. Repression of NF-kappaB and activation of AP-1 enhance apoptosis in prostate cancer cells. Int J Cancer 2009; 124:1980-9. PubMed
  • Ganapathy M,Ghosh R,Jianping X,Zhang X,Bedolla R,Schoolfield J,Yeh IT,Troyer DA,Olumi AF,Kumar AP. Involvement of FLIP in 2-methoxyestradiol-induced tumor regression in transgenic adenocarcinoma of mouse prostate model. Clin Cancer Res 2009; 15:1601-11. PubMed
  • Olumi AF,Dewolf WC. The hybrid of basic science and clinical training for the urologic oncologit: Necessity or waste? Urol Oncol 2009; 27:205-7. PubMed
  • Pedrosa I,Sun MR,Spencer M,Genega EM,Olumi AF,Dewolf WC,Rofsky NM. MR imaging of renal masses: correlation with findings at surgery and pathologic analysis. Radiographics 2008; 28:985-1003. PubMed
  • Zhang X, Li W, Olumi AF. Low-dose 12-O-tetradecanoylphorbol-13-acetate enhances tumor necrosis factor related apoptosis-inducing ligand induced apoptosis in prostate cancer cells. Clin Cancer Res 2007; 13:7181-90. PubMed
  • Huang X, Zhang X, Farahvash B, Olumi AF. Novel targeted pro-apoptotic agents for the treatment of prostate cancer. J Urol 2007; 178:1846-54. PubMed
  • Yang H, Minamishima YA, Yan Q, Schlisio S, Ebert BL, Zhang X, Zhang L, Kim WY, Olumi AF, Kaelin WG. pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2. Mol Cell 2007; 28:15-27. PubMed
  • Li W, Wu CL, Febbo PG, Olumi AF. Stromally expressed c-Jun regulates proliferation of prostate epithelial cells. Am J Pathol 2007; 171:1189-98. PubMed
  • Zhang X, Zhang L, Yang H, Huang X, Otu H, Libermann TA, DeWolf WC, Khosravi-Far R, Olumi AF. c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res 2007; 67:9425-34. PubMed
  • Li L, Zhang L, Zhang X, Yan Q, Minamishima YA, Olumi AF, Mao M, Bartz S, Kaelin WG. HIF LINKED TO DIFFERENTIAL KIDNEY CANCER RISK SEEN WITH TYPE 2A AND TYPE 2B VHL MUTATIONS. Mol Cell Biol 2007; 27:5381-92. PubMed
  • Zhang L, Zhang X, Barrisford GW, Olumi AF. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett 2007; 251:146-57. PubMed
  • Li W, Zhang X, Olumi AF. MG-132 Sensitizes TRAIL-Resistant Prostate Cancer Cells by Activating c-Fos/c-Jun Heterodimers and Repressing c-FLIP(L). Cancer Res 2007; 67:2247-55. PubMed
  • San Francisco IF, Regan MM, Dewolf WC, Olumi AF. Low age adjusted free testosterone levels correlate with poorly differentiated prostate cancer. J Urol 2006; 175:1341-5; discussion 1345-6. PubMed
Hide
Visualize Collaborations
Learn how these members are similar
Similar Members

HCC members that share similar concepts* with Aria F. Olumi, MD but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members